270 related articles for article (PubMed ID: 26520442)
1. HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC).
Lopes-Coelho F; Gouveia-Fernandes S; Gonçalves LG; Nunes C; Faustino I; Silva F; Félix A; Pereira SA; Serpa J
Tumour Biol; 2016 Apr; 37(4):4813-29. PubMed ID: 26520442
[TBL] [Abstract][Full Text] [Related]
2. Metabolic alterations caused by HNF1β expression in ovarian clear cell carcinoma contribute to cell survival.
Amano Y; Mandai M; Yamaguchi K; Matsumura N; Kharma B; Baba T; Abiko K; Hamanishi J; Yoshioka Y; Konishi I
Oncotarget; 2015 Sep; 6(28):26002-17. PubMed ID: 26318292
[TBL] [Abstract][Full Text] [Related]
3. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
4. OSI-906 restores the sensitivity of ovarian clear cell carcinoma to cisplatin by targeting the IGF1R/AKT pathway.
Liu L; Liang C; Zhuo C; Jiang H; Ye H; Ruan T; Song J; Jiang S; Zhang Y; Li X
Med Oncol; 2022 Jan; 39(2):26. PubMed ID: 34982265
[TBL] [Abstract][Full Text] [Related]
5. Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
Bixel K; Saini U; Kumar Bid H; Fowler J; Riley M; Wanner R; Deepa Priya Dorayappan K; Rajendran S; Konishi I; Matsumura N; Cohn DE; Selvendiran K
Int J Cancer; 2017 Nov; 141(9):1856-1866. PubMed ID: 28646535
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte nuclear factor-1β (HNF-1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma.
Okamoto T; Mandai M; Matsumura N; Yamaguchi K; Kondoh H; Amano Y; Baba T; Hamanishi J; Abiko K; Kosaka K; Murphy SK; Mori S; Konishi I
Mol Carcinog; 2015 Jan; 54(1):35-49. PubMed ID: 24105991
[TBL] [Abstract][Full Text] [Related]
7. Minimal ovarian upregulation of glutamate cysteine ligase expression in response to suppression of glutathione by buthionine sulfoximine.
Hoang YD; Avakian AP; Luderer U
Reprod Toxicol; 2006 Feb; 21(2):186-96. PubMed ID: 16183247
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Kuroda T; Ogiwara H; Sasaki M; Takahashi K; Yoshida H; Kiyokawa T; Sudo K; Tamura K; Kato T; Okamoto A; Kohno T
Gynecol Oncol; 2019 Dec; 155(3):489-498. PubMed ID: 31604667
[TBL] [Abstract][Full Text] [Related]
9. Ovarian clear cell carcinoma meets metabolism; HNF-1β confers survival benefits through the Warburg effect and ROS reduction.
Mandai M; Amano Y; Yamaguchi K; Matsumura N; Baba T; Konishi I
Oncotarget; 2015 Oct; 6(31):30704-14. PubMed ID: 26375553
[TBL] [Abstract][Full Text] [Related]
10. Targeting PDGF signaling of cancer-associated fibroblasts blocks feedback activation of HIF-1α and tumor progression of clear cell ovarian cancer.
Mori Y; Okimoto Y; Sakai H; Kanda Y; Ohata H; Shiokawa D; Suzuki M; Yoshida H; Ueda H; Sekizuka T; Tamura R; Yamawaki K; Ishiguro T; Mateos RN; Shiraishi Y; Yatabe Y; Hamada A; Yoshihara K; Enomoto T; Okamoto K
Cell Rep Med; 2024 May; 5(5):101532. PubMed ID: 38670097
[TBL] [Abstract][Full Text] [Related]
11.
Kawahara N; Yamada Y; Kobayashi H
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
[TBL] [Abstract][Full Text] [Related]
12. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
13. c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma.
Kim HJ; Yoon A; Ryu JY; Cho YJ; Choi JJ; Song SY; Bang H; Lee JS; Cho WC; Choi CH; Lee JW; Kim BG; Bae DS
Sci Rep; 2016 Dec; 6():38502. PubMed ID: 27917934
[TBL] [Abstract][Full Text] [Related]
14. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217
[TBL] [Abstract][Full Text] [Related]
15. EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2/BCL-X
Inoue-Yamauchi A; Oda H
Biochem Biophys Res Commun; 2020 Jun; 526(3):612-617. PubMed ID: 32247610
[TBL] [Abstract][Full Text] [Related]
16. Loss of autophagy-related protein Beclin 1 may define poor prognosis in ovarian clear cell carcinomas.
Katagiri H; Nakayama K; Razia S; Nakamura K; Sato E; Ishibashi T; Ishikawa M; Iida K; Ishikawa N; Otsuki Y; Nakayama S; Kyo S
Int J Oncol; 2015 Dec; 47(6):2037-44. PubMed ID: 26458502
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.
Matsumura N; Mandai M; Okamoto T; Yamaguchi K; Yamamura S; Oura T; Baba T; Hamanishi J; Kang HS; Matsui S; Mori S; Murphy SK; Konishi I
Cancer Sci; 2010 Dec; 101(12):2658-63. PubMed ID: 21040214
[TBL] [Abstract][Full Text] [Related]
18. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
Kim M; Lu F; Zhang Y
Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin.
Sirichaisutdhikorn D; Suprasert P; Khunamornpong S
Asian Pac J Cancer Prev; 2009; 10(6):1041-5. PubMed ID: 20192580
[TBL] [Abstract][Full Text] [Related]
20. The subunits of glutamate cysteine ligase enhance cisplatin resistance in human non-small cell lung cancer xenografts in vivo.
Fujimori S; Abe Y; Nishi M; Hamamoto A; Inoue Y; Ohnishi Y; Nishime C; Matsumoto H; Yamazaki H; Kijima H; Ueyama Y; Inoue H; Nakamura M
Int J Oncol; 2004 Aug; 25(2):413-8. PubMed ID: 15254739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
